Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-07-03T11:46:55.229Z Has data issue: false hasContentIssue false

Chap. 23 - EMERGENCY MANAGEMENT OF PURPURA AND VASCULITIS, INCLUDING PURPURA FULMINANS

Published online by Cambridge University Press:  07 September 2011

Lucio Andreassi
Affiliation:
University of Siena
Roberta Bilenchi
Affiliation:
University of Siena
Ronni Wolf
Affiliation:
Kaplan Medical Center, Rehovot, Israel
Batya B. Davidovici
Affiliation:
Kaplan Medical Center, Rehovot, Israel
Jennifer L. Parish
Affiliation:
Jefferson Medical College of Thomas Jefferson University
Lawrence Charles Parish
Affiliation:
Jefferson Medical College of Thomas Jefferson University
Get access

Summary

PURPURIC LESIONS are the clinical expression of the passage of erythrocytes from the vascular compartment to the extravascular one, generally following damage related to permeabilization of the walls of small vessels. At times, they are the only clinical feature, at other times the sign of a more complex morbid process and the expression of a serious condition, as in the systemic vasculitides.

The clinical spectra of vasculitides are broad, with a variety of conditions ranging from mainly cutaneous involvement with a relatively benign course, such as leukocytoclastic vasculitis, to situations in which the cutaneous involvement is less evident but an integral part of a process that could progress to a critical situation requiring emergency treatment. Acute pulmonary insufficiency or renal blockage, as an expression of a systemic vasculitis, is relatively frequent in intensive care units. Central and peripheral nervous system involvement, cardiac failure, and intestinal ischemia, as complications or first presenting signs of systemic vasculitides, are clinical conditions commonly encountered in current practice. Purpura fulminans (PF), often associated with disseminated intravascular coagulation (DIC), is a dramatic condition that must be identified correctly and differentiated from purpura simplex.

Type
Chapter
Information
Emergency Dermatology , pp. 233 - 244
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cruz, BA, Ramanoelina, J, Mahr, A, et al. Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology. 2003; 42:1183–8.CrossRefGoogle ScholarPubMed
Semple, D, Keogh, J, Forni, L, Venn, R. Clinical review: vasculitis on the intensive care unit-part 1: diagnosis. Crit Care. 2005; 9:92–7.CrossRefGoogle ScholarPubMed
Younger, DS. Vasculitis of the nervous system. Curr Opin Neurol. 2004; 17:317–36.CrossRefGoogle Scholar
Specker, C. Das Herz bei rheumatologischen Erkrankungen. Internist (Berl). 2007; 48:284–9.CrossRefGoogle Scholar
Passam, FH, Diamantis, ID, Perisinaki, G, et al. Intestinal ischemia as the first manifestation of vasculitis. Semin Arthritis Rheum. 2004; 34:431–41.CrossRefGoogle ScholarPubMed
Davis, MD, Dy, KM, Nelson, S. Presentation and outcome of purpura fulminans associated with peripheral gangrene in 12 patients at Mayo Clinic. J Am Acad Dermatol. 2007; 57:944–56.CrossRefGoogle ScholarPubMed
Slobodin, G, Hussein, A, Rozenbaum, M, Rosner, I. The emergency room in systemic rheumatic diseases. Emerg Med J. 2006; 23:667–71.CrossRefGoogle ScholarPubMed
Roberts, PF, Waller, TA, Brinker, TM, et al. Henoch-Schönlein purpura: a review article. South Med J. 2007; 100:821–4.CrossRefGoogle ScholarPubMed
Trapani, S, Micheli, A, Grisolia, F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum. 2005; 35:143–53.CrossRefGoogle Scholar
Ozen, S, Ruperto, N, Dillon, MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006; 65:936–41.CrossRefGoogle ScholarPubMed
Mohammad, AJ, Jacobsson, LT, Mahr, AD, et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology. 2007; 46:1329–37.CrossRefGoogle ScholarPubMed
Mahr, A, Guillevin, L, Poissonnet, M, Aymé, S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004; 51:92–9.CrossRefGoogle Scholar
Lind van Wijngaarden, RA, Rijn, L, Hagen, EC, et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol. 2008; 3:237–52.CrossRefGoogle ScholarPubMed
Talor, MV, Stone, JH, Stebbing, J, et al. Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol. 2007; 150:42–8.CrossRefGoogle Scholar
Lamprecht, P, Gross, WL. Current knowledge on cellular interactions in the WG-granuloma. Clin Exp Rheumatol. 2007; 25:S49–51.Google ScholarPubMed
Kallenberg, CG, Heeringa, P, Stegeman, CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol. 2006; 2:661–70.CrossRefGoogle ScholarPubMed
DeRemee, RA. Trimethoprim-sulphamethoxazole for the treatment of Wegener's granulomatosis. Rheumatology. 2003; 42:396.CrossRefGoogle ScholarPubMed
Ben, Ghorbel I, Dhrif, AS, Miled, M, Houman, MH. Atteintes cutanées révélatrices d'une granulomatose de Wegener. Presse Med. 2007; 36:619–22.Google Scholar
Keogh, KA, Specks, U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003; 115:284–90.CrossRefGoogle ScholarPubMed
Lhote, F. Syndrome de Churg et Strauss. Presse Med. 2007; 36:875–89.CrossRefGoogle ScholarPubMed
Tomassini, C, Seia, Z. Churg-Strauss sindrome. G Ital Dermatol Venereol. 2004; 139:485–91.Google Scholar
Davis, MD, Daoud, MS, McEvoy, MT, Su, WP. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol. 1997; 37:199–203.CrossRefGoogle ScholarPubMed
Kawakami, T, Soma, Y, Kawasaki, K, et al. Initial cutaneous manifestations consistent with mononeuropathy multiplex in Churg-Strauss syndrome. Arch Dermatol. 2005; 141:873–8.CrossRefGoogle ScholarPubMed
Jennette, JC, Falk, RJ. The role of pathology in the diagnosis of systemic vasculitis. Clin Exp Rheumatol. 2007; 25(1 Suppl 44):S52–6.Google Scholar
Haubitz, M. ANCA-associated vasculitis: diagnosis, clinical characteristics and treatment. Vasa. 2007; 36:81–9.CrossRefGoogle ScholarPubMed
Ozaki, S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007; 56:87–96.CrossRefGoogle ScholarPubMed
Pagnoux, C, Guilpain, P, Guillevin, L. Churg-Strauss syndrome. Curr Opin Rheumatol. 2007; 19:25–32.CrossRefGoogle ScholarPubMed
Díaz-Pérez, JL, Lagrán, ZM, Díaz-Ramón, JL, Winkelmann, RK. Cutaneous polyarteritis nodosa. Semin Cutan Med Surg. 2007; 26:77–86.CrossRefGoogle ScholarPubMed
Janssen, HL, Zonneveld, M, Nunen, AB, et al. Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol. 2004; 16:801–7.CrossRefGoogle ScholarPubMed
Guillevin, L, Mahr, A, Callard, P, et al. French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine. 2005; 84:313–22.CrossRefGoogle Scholar
Pagnoux, C, Guilpain, P, Guillevin, L. Polyangéite microscopique. Presse Med. 2007; 36:895–901.CrossRefGoogle Scholar
Kallenberg, CG. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Curr Opin Rheumatol. 2007; 19:17–24.CrossRefGoogle ScholarPubMed
Guillevin, L, Durand-Gasselin, B, Cevallos, R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999; 42:421–30.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
Kawakami, T, Kawanabe, T, Saito, C, et al. Clinical and histopathologic features of 8 patients with microscopic polyangiitis including two with a slowly progressive clinical course. J Am Acad Dermatol. 2007; 57:840–8.CrossRefGoogle ScholarPubMed
Seishima, M, Oyama, Z, Oda, M. Skin eruptions associated with microscopic polyangiitis. Eur J Dermatol. 2004; 14:255–8.Google ScholarPubMed
Lane, SE, Watts, R, Scott, DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005; 7:270–5.CrossRefGoogle ScholarPubMed
Newburger, JW, Takahashi, M, Gerber, MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004; 114:1708–33.CrossRefGoogle Scholar
Naoe, S, Takahashi, K, Masuda, H, Tanaka, N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 1991; 41:785–97.Google ScholarPubMed
Royle, J, Burgner, D, Curtis, N. The diagnosis and management of Kawasaki disease. J Paediatr Child Health. 2005; 41:87–93.CrossRefGoogle ScholarPubMed
Gouveia, C, Brito, MJ, Ferreira, GC, et al. Kawasaki disease. Rev Port Cardiol. 2005; 24:1097–113.Google ScholarPubMed
Kato, H, Sugimura, T, Akagi, T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996; 94:1379–85.CrossRefGoogle ScholarPubMed
Levy, DM, Silverman, ED, Massicotte, MP, et al. Longterm outcomes in patients with giant aneurysms secondary to Kawasaki disease. J Rheumatol. 2005; 32:928–34.Google ScholarPubMed
Daniels, SR, Specker, B, Capannari, TE, et al. Correlates of coronary artery aneurysm formation in patients with Kawasaki disease. Am J Dis Child. 1987; 141:205–7.Google ScholarPubMed
Schellongowski, P, Bauer, E, Holzinger, U, et al. Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin). Vox Sang. 2006; 90:294–301.CrossRefGoogle Scholar
Vincent, JL, Nadel, S, Kutsogiannis, DJ, et al. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. Crit Care. 2005; 9:R331–43.CrossRefGoogle ScholarPubMed
Lee, JH, Song, JW, Song, KS. Diagnosis of overt disseminated intravascular coagulation: a comparative study using criteria from the International Society versus the Korean Society on Thrombosis and Hemostasis. Yonsei Med J. 2007; 48:595–600.CrossRefGoogle ScholarPubMed
Franchini, M. Pathophysiology, diagnosis and treatment of disseminated intravascular coagulation: an update. Clin Lab. 2005; 51:633–9.Google ScholarPubMed
DeLoughery, TG. Critical care clotting catastrophies. Crit Care Clin. 2005; 21:531–62.CrossRefGoogle ScholarPubMed
Gaskin, G, Pusey, CD. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher. 2001; 5:176–81.CrossRefGoogle ScholarPubMed
Jayne, DR, Gaskin, G, Rasmussen, N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 18:2180–8.CrossRefGoogle ScholarPubMed
Jayne, D, Rasmussen, N, Andrassy, K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349:36–44.CrossRefGoogle ScholarPubMed
Jayne, DR, Chapel, H, Adu, D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000; 93:433–9.CrossRefGoogle ScholarPubMed
Booth, A, Harper, L, Hammad, T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004; 15:717–21.CrossRefGoogle ScholarPubMed
Keogh, KA, Ytterberg, SR, Fervenza, FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006; 173:180–7.CrossRefGoogle ScholarPubMed
Ronkainen, J, Koskimies, O, Ala-Houhala, M, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006; 149:241–7.CrossRefGoogle ScholarPubMed
Dillon, MJ. Henoch-Schönlein purpura: recent advances. Clin Exp Rheumatol. 2007; 25(1 Suppl 44):S66–8.Google ScholarPubMed
Zaffanello, M, Brugnara, M, Franchini, M. Therapy for children with Henoch-Schonlein purpura nephritis: a systematic review. ScientificWorldJournal. 2007; 7:20–30.CrossRefGoogle ScholarPubMed
Lamireau, T, Rebouissoux, L, Hehunstre, JP. Intravenous immunoglobulin therapy for severe digestive manifestations of Henoch-Schönlein pur pura. Acta Paediatr. 2001; 90:1081–2.CrossRefGoogle Scholar
Shenoy, M, Ognjanovic, MV, Coulthard, MG. Treating severe Henoch-Schönlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol. 2007; 22:1167–71.CrossRefGoogle ScholarPubMed
Lamprecht, P, Till, A, Steinmann, J, et al. Current state of biologicals in the management of systemic vasculitis. Ann NY Acad Sci. 2007; 1110:261–70.CrossRefGoogle ScholarPubMed
Yazici, Y. Vasculitis update, 2007. Bull NYU Hosp Jt Dis. 2007; 65:212–14.Google ScholarPubMed
Wung, PK, Stone, JH. Therapeutics of Wegener's granulomatosis. Nat Clin Pract Rheumatol. 2006; 2:192–200.CrossRefGoogle ScholarPubMed
,Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005; 352:351–61.CrossRefGoogle Scholar
Mukhtyar, C, Luqmani, R. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis. 2005; 64 Suppl 4:31–6.CrossRefGoogle ScholarPubMed
Antoniu, SA. Treatment options for refractory Wegener's granulomatosis: a role for rituximab?Curr Opin Investig Drugs. 2007; 8:927–32.Google ScholarPubMed
Metzler, C, Miehle, N, Manger, K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology. 2007; 46:1087–91.CrossRefGoogle ScholarPubMed
Langford, CA, Talar-Williams, C, Sneller, MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum. 2004; 51:278–83.CrossRefGoogle ScholarPubMed
Schmitt, WH, Birck, R, Heinzel, PA, et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant. 2005; 20:1083–92.CrossRefGoogle ScholarPubMed
Hellmich, B, Gross, WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother. 2004; 5:25–35.CrossRefGoogle ScholarPubMed
Arbach, O, Gross, WL, Gause, A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology. 2002; 206:496–501.CrossRefGoogle ScholarPubMed
Kaushik, VV, Reddy, HV, Bucknall, RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006; 65:1116–17.CrossRefGoogle Scholar
Koukoulaki, M, Smith, KG, Jayne, DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis. 2006; 65:557–9.CrossRefGoogle ScholarPubMed
Taniguchi, M, Tsurikisawa, N, Higashi, N, et al. Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int. 2007; 56:97–103.CrossRefGoogle ScholarPubMed
Colmegna, I, Maldonado-Cocco, JA. Polyarteritis nodosa revisited. Curr Rheumatol Rep. 2005; 7:288–96.CrossRefGoogle ScholarPubMed
Guillevin, L, Pagnoux, C. Therapeutic strategies for systemic necrotizing vasculitides. Allergol Int. 2007; 56:105–11.CrossRefGoogle ScholarPubMed
Takeshita, S, Nakamura, H, Kawakami, A, et al. Hepatitis B-related polyarteritis nodosa presenting necrotizing vasculitis in the hepatobiliary system successfully treated with lamivudine, plasmapheresis and glucocorticoid. Intern Med. 2006; 45:145–9.CrossRefGoogle ScholarPubMed
Deléaval, P, Stadler, P, Descombes, E, et al. Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids. Clin Rheumatol. 2001; 20:290–2.CrossRefGoogle ScholarPubMed
Lau, CF, Hui, PK, Chan, WM, et al. Hepatitis B associated fulminant polyarteritis nodosa: successful treatment with pulse cyclophosphamide, prednisolone and lamivudine following emergency surgery. Eur J Gastroenterol Hepatol. 2002; 14:563–6.CrossRefGoogle ScholarPubMed
Langford, CA. Small-vessel vasculitis: therapeutic management. Curr Rheumatol Rep. 2007; 9:328–35.CrossRefGoogle ScholarPubMed
Hoffman, GS, Langford, CA. Can methotrexate replace cyclophosphamide in the treatment of a subset of Wegener's granulomatosis and microscopic polyangiitis?Nat Clin Pract Rheumatol. 2006; 2:70–1.CrossRefGoogle ScholarPubMed
De Rosa, G, Pardeo, M, Rigante, D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007; 11:301–8.Google ScholarPubMed
Durongpisitkul, K, Gururaj, VJ, Park, JM, Martin, CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995; 96:1057–61.Google ScholarPubMed
Newburger, JW, Takahashi, M, Burns, JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986; 315:341–7.CrossRefGoogle ScholarPubMed
Marasini, M, Pongiglione, G, Gazzolo, D, et al. Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities. Am J Cardiol. 1991; 68:796–7.CrossRefGoogle ScholarPubMed
Sundel, RP, Baker, AL, Fulton, DR, Newburger, JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003; 142:611–16.CrossRefGoogle ScholarPubMed
Furukawa, S, Matsubara, T, Umezawa, Y, et al. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr. 1994; 153:663–7.CrossRefGoogle ScholarPubMed
Weiss, JE, Eberhard, BA, Chowdhury, D, Gottlieb, BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004; 31:808–10.Google ScholarPubMed
Carey, MJ, Rodgers, GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol. 1998; 59:65–73.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Toh, CH, Downey, C. Back to the future: testing in disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2005; 16:535–42.CrossRefGoogle ScholarPubMed
Feinstein, DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood. 1982; 60:284–7.Google ScholarPubMed
Ewing, CI, David, TJ, Davenport, PJ. Heparin for uncontrolled disseminated intravascular coagulation in meningococcal septicaemia. J R Soc Med. 1989; 82:762–3.CrossRefGoogle ScholarPubMed
Hjort, PF, Rapaport, SI, Jorgensen, L. Purpura fulminans. Report of a case successfully treated with heparin and hydrocortisone. Review of 50 cases from the literature. Scand J Haematol. 1964; 61:169–92.Google Scholar
Oguma, Y, Sakuragawa, N, Maki, M, et al. Treatment of disseminated intravascular coagulation with low molecular weight heparin. Research Group of FR-860 on DIC in Japan. Semin Thromb Hemost. 1990; 16 Suppl:34–40.Google ScholarPubMed
Smith, OP, White, B. Infectious purpura fulminans: caution needed in the use of protein C. Br J Haematol. 1999; 106:253–4.CrossRefGoogle ScholarPubMed
Sen, K, Roy, A. Management of neonatal purpura fulminans with severe protein C deficiency. Indian Pediatr. 2006; 43:542–5.Google ScholarPubMed
Müller, FM, Ehrenthal, W, Hafner, G, Schranz, D. Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr. 1996; 155:20–5.CrossRefGoogle ScholarPubMed
de Kleijn, ED, de Groot, R, Hack, CE, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med. 2003; 31:1839–47.CrossRefGoogle ScholarPubMed
Kaiserman, D, Whisstock, JC, Bird, PI. Mechanisms of serpin dysfunction in disease. Expert Rev Mol Med. 2006; 8:1–19.CrossRefGoogle Scholar
Afshari, A, Wetterslev, J, Brok, J, Møller, A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ. 2007; 335:1248–51.CrossRefGoogle ScholarPubMed
Darmstadt, GL. Acute infectious purpura fulminans: pathogenesis and medical management. Pediatr Dermatol. 1998; 15:169–83.CrossRefGoogle ScholarPubMed
Twomey, JA, Peltier, GL, Zera, RT. An open-label study to evaluate the safety and efficacy of tissue plasminogen activator in treatment of severe frostbite. J Trauma. 2005; 59:1350–4.CrossRefGoogle ScholarPubMed
Spronk, PE, Rommes, JH, Schaar, C, Ince, C. Thrombolysis in fulminant purpura: observations on changes in microcirculatory perfusion during successful treatment. Thromb Haemost. 2006; 95:576–8.Google ScholarPubMed
Zenz, W, Zoehrer, B, Levin, M, et al. Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study. Crit Care Med. 2004; 32:1777–80.CrossRefGoogle ScholarPubMed
Baines, P, Carrol, ED. Recombinant tissue plasminogen activator in children with meningococcal purpura fulminans–role uncertain. Crit Care Med. 2004; 32:1806–7.CrossRefGoogle ScholarPubMed
Winrow, AP. Successful treatment of neonatal purpura fulminans with epoprostenol. J R Soc Med. 1992; 85:245.Google ScholarPubMed
Stewart, FJ, McClure, BG, Mayne, E. Successful treatment of neonatal purpura fulminans with epoprostenol. J R Soc Med. 1991; 84:623–4.Google ScholarPubMed
Roderick, P, Ferris, G, Wilson, K, et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess. 2005; 9:1–78.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×